PRECISION BIOSCIENCES INC 8-K

What Happened

• Precision BioSciences, Inc. held its annual meeting on May 21, 2026 and filed an 8‑K on May 26, 2026 reporting the results. About 22,304,867 shares were represented (≈86% of outstanding as of the March 25, 2026 record date).
• Shareholders elected Melinda Brown and Geno Germano as Class I directors and approved several proposals, including an amendment to the 2019 Incentive Award Plan to add 3,800,000 shares and an amendment to the Certificate of Incorporation to permit officer exculpation under Delaware law (filed and effective May 22, 2026).

Key Details

• Vote turnout: ~22.3M shares present or represented, ~86% of outstanding stock (record date March 25, 2026).
• 2019 Incentive Award Plan: amended and restated to increase the share pool by 3,800,000 shares; Proposal 4 approved (For: 11,170,635; Against: 8,145,992; Abstain: 10,906; Broker non‑votes: 2,977,334).
• Director elections: Melinda Brown (For: 14,348,888; Withheld: 4,978,645) and Geno Germano (For: 14,288,270; Withheld: 5,039,263) were elected.
• Certificate amendment: stockholders approved officer exculpation under Delaware law; the amendment was filed with Delaware on May 22, 2026 and became effective upon filing.
• Other approvals: ratification of Deloitte & Touche LLP as auditor and the advisory (non‑binding) approval of named executive officer compensation (say‑on‑pay).

Why It Matters

• The 3.8M‑share increase to the incentive award plan expands the equity available for employee and executive compensation, which can affect share dilution and future equity expense.
• Election of directors and approval of officer exculpation are governance items that influence board composition and legal protections for officers.
• High shareholder participation and approval of routine items (auditor ratification, say‑on‑pay) indicate investor support for the company’s governance and compensation approach.